GCM
RXRX icon

Graham Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Graham Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6K Buy
+12,257
New +$47.4K ﹤0.01% 1101
2022
Q4 		– Sell
-123,702
Closed -$1.32M – 1306
2022
Q3 		$1.32M Buy
123,702
+80,505
+186% +$815K 0.05% 365
2022
Q2 		$351K Buy
+43,197
New +$289K 0.01% 773

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Graham Capital Management's RXRX Position: Q1 2026 in Review

Graham Capital Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 12,257 shares worth $37.6K. The stake represents ﹤0.01% of the portfolio and ranks #1101 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in RXRX as recently as Q3 2022.

Graham Capital Management first reported a position in RXRX in Q2 2022 and has held it in 3 quarters since. The position peaked at $1.32M in Q3 2022. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Graham Capital Management held 12,257 shares of Recursion Pharmaceuticals worth $37.6K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Graham Capital Management position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1101 holding.
  • Graham Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
  • Graham Capital Management's Recursion Pharmaceuticals position peaked at $1.32M in Q3 2022.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.